Tavist

(Clemastine)

Phase 2Small molecule

HHALEON

Tavist is one of 127 small molecule programs targeting Urticaria. It is currently in Phase 2.

Indications

Total Trials

Active Trials

126

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

UrticariaActive, not recruiting

Multiple SclerosisActive, not recruiting

SchizophreniaActive, not recruiting

Optic NeuritisActive, not recruiting

UrticariaPhase 2

Active, not recruiting

Multiple SclerosisPhase 2

Active, not recruiting

SchizophreniaPhase 2

Active, not recruiting

Optic NeuritisPhase 2

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Tavist

HHALEON

Phase 2

1 2

Celexa

AbbVie

Preclinical

4 3

Ozempic

Novo Nordisk

Preclinical

1 4

Resotran

Takeda

Preclinical

1 5

Depakote

Lunesta

3 7

Permax

VValeant Pharmaceuticals

Preclinical

1 8

Luvox

SSolvay Pharmaceuticals

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

Vivarin

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Not yet recruiting

Schizophrenia

NCT06315972

Q3 2028

Phase 2Recruiting

Optic Neuritis

NCT02521311

Clinical

Trials by Indication[1]

Cardiovascular Surgery1 trial

Clemastine in Cardiovascular Surgery

Completed·—·N/A·NCT03826004·100 enrolled

Optic Neuritis1 trial

Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

Recruiting·UUniversity of California, San Francisco·Phase 2·NCT02521311·90 enrolled

Urticaria1 trial

Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria

Completed· Novartis logo

Novartis·Phase 2·NCT00481676·49 enrolled

Schizophrenia1 trial

Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity

Not yet recruiting·LLMU Klinikum·Phase 2·NCT06315972·90 enrolled

Multiple Sclerosis1 trial

Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis

Completed·UUniversity of California, San Francisco·Phase 2·NCT02040298·50 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

TAVIST

NDA NDA017661

Jun 28, 1985

TAVIST

NDA NDA018675

Aug 21, 1992

TAVIST-1

NDA NDA020925

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Clemastine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Clemastine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Clemastine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020925). U.S. Food & Drug Administration.
[5]
SEC EDGAR — HALEON company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHALEON

Tavist

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q3 2028

Trials by Indication[1]

Cardiovascular Surgery1 trial

Optic Neuritis1 trial

Urticaria1 trial

Schizophrenia1 trial

Multiple Sclerosis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News